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drug information
Question: What is the risk of teratogenicity with the use of selective serotonin
reuptake inhibitors during pregnancy?

Michael Z. Wincor, Pharm.D., Ma/Y A. Gutierrez, Pharm.D., Ann Nguyen

Background
The lifetime prevalence of major depressive disorder
in women is 10 to 25%, with an average age of onset in
the mid-20s. 1 Over the nine years that the selective
serotonin reuptake inhibitors (SSRis) have been available, for many prescribers, they have become first-line
agents in the treatment of depression. In addition, sorne
of them are also being used in the treatment of obsessive-compulsive disorder and panic disorder. In light of
these facts, itis not unlikely that women of childbearing
age would be treated with one of the SSRis.
In considering the risks of exposing a fetus to an
SSRI, both structural malformation (i.e., teratogenesis)
and long-term behavioral effects (i.e., behavioral teratogenesis) must be considered; in addition, possible
si de effects and withdrawal syndromes in the newborn
must be assessed. It is impossible to be certain that any
drug is absolutely safe for use in pregnancy; hence, only
an estimate of relative risk can be attempted.

Findings
Most of the data available regarding the effects of
SSRis on the fetus involve the use of fluoxetine. In 1993,
Pastuszak and coworkers reported on pregnancy outcome in 128 pregnant women exposed to fluoxetine in
the first trimester as compared with two matchedgroups
of women exposed during the first trimester to either
tricyclic antidepressants or agents thought to be
nonteratogens. 2 They concluded that use of fluoxetine
during embryogenesis is not associated with an increased risk of major malformations. \Vomen exposed
to both fluoxetine and tricyclic antidepressants tended
to report higher rates of rniscarriage; however, the
investigators could not separate the effects of the psychiatrie condition from the associated drugs. Goldstein
later reported for the manufacturer of fluoxetine, based
on 112 prospectivelyidentifiedfluoxetine-exposed pregnancies and a comparison with reported rates from the
National Hospital Discharge Survey, that it is unlikely
that maternai fluoxetine use during the third trimester
results in significant postnatal complications. 3
In 1996, Baum and Misri reviewed the literature on
the effects of SSRis during pregnancy and lactation. 4
They found an increased rate of miscarriage, a greater
tendency for infants to be large for their gestational age,
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and one report of perinatal toxicity. In the same year
Nulman and Koren reported their preliminary finding;
regarding fluoxetine.~ They evaluated the neurobehav.
ioral development of 3 7 children exposcd to t1uoxetine
during the first trimester and 18 infants who were
exposed to the drug throughout pregnancy. They re.
ported no significant difference in intelligence quotient
(IQ) between fluoxetine-exposed children and contrais
and concluded that fluoxetine, in recommended doses
is not associated with an increased frequency of struc~
tural abnormalities or neurobehavioral irnpairment.
Chambers and coworkers prospectively studied 228
women taking fluoxetine who had called the California
Teratogen Information Service and Clinical Rcsearch
Pro gram over a six year period and compared them with
254 pregnant women who had called the service with
questions regarding drugs and procedures considcred
not to be teratogenic. 6 Approxima tel y one thire! of the
fluoxetine-treated group took other psychotropic agents,
usually a benzodiazepine or other antidepressant. No
significant differences were noted betwecn groups with
respect to spontaneous pregnancy loss or major structural abnorn1alitîes. However, the proportion of children with three or more min or anomalies (structural
defects with no functional or cosrnetic significancc) was
significantly higher in the fluoxetine group (15. 5%) than
in the control group (6.5%). Whether or not children
born with three or more minor anomalies are more
likely later to develop major structural anomalies is
un certain. The rate of premature deliveries was h igher
in the women who had taken fluoxetine la ter in pregnancy~(14.3%) than in those exposed in the first and
second trimesters ( 4.1%) or not at ali (5.9%). "\lso,
infants exposed to fluoxetine later in pregnancy had
higher rates of admission to special-care nurseries (23Wl),
poor neonatal adaptation (including respiratory difficulty, cyanosis on feeding, and jittering), and lower
birth weight.
An editorial, by Elizabeth Robert, accompanying the
Chambers report, however, identifies sevcral flaws in
study design. 7 The study was not randomized; the
contribution of maternai depressive illness to hirth
outcomes was not excluded; the fluoxetine- treated group
may not have been adequately matched with the control group (i.e., maternai age was higher in the womcn
taking fluoxetine than in the contrais and maternai
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weight gain differed between women who had taken
fluoxetine early in pregnancy and those who had taken
it later which could have accounted for much of the
difference in infant birth weights). Robert, therefore,
argues that this study provides insufficient evidence to
withhold fluoxetine from women who require it during
pregnancy.
Most recently, Nul man and coworkers reported their

updated findings in the children of 80 mothers who had
received a tricyclic antidepressant drug during pregnancy, 55 children wh ose mothers had received
fluoxetine during pregnancy, and 84 children whose
mothers had not been exposed during pregnancy to any
agentkuown to affect the fetus adversely 8 The children's
global IQ and language development were assessed
between 16 and 86 months of postnatal age. The mean
IQ scores were 118 in the children of tricyclic-treated
mothers, 117 in those of fluoxetine-treated mothers,
and 115 in those in the control group; in addition, the
language skills were similar in ali three groups. The
results were similar in children exposed to a tricyclic
antidepressant or fluoxetine during the first trimester
and those exposed throughout pregnancy. No significant differences in temperament, mood, arousability,
activity leve!, distractibility, or behavior problems in
the three groups of children were noted. The authors
concluded that in utero exposure to either tricyclic
antidepressants or fluoxetine does not affect global IQ,
language development, or behavioral development in
preschool children.

Conclusion
There may be sorne risk of adverse effects on the
newborn associated with the use of fluoxetine during
pregnancy, especially when taken late in pregnancy.
However, the currently available literature leaves the
issue incompletely answered. In addition, there is no
information on possible teratogenic effects that may
become apparent in adolescence or adulthood. To complicate the matter further, the teratogenic potential of
untreated major depression in the pregnant woman is
unknown. It is clear, however, that there is considerable morbidity and mortality associated with depressive illness. Hence, if SSRI treatment is being considered in a woman of childbearing age, an agent with a
relatively short half-life (e.g., sertraline or paroxetine)
could be considered rather than fluoxetine; if preg-

be informed of the potential risks -

both lmown and

unknown - of drug treatment, as well as lack of treat.
ment, and a decision needs to be made in collaborau 0

with the prescriber. That such an informed, collabar:
tive decision has been made should be clearly documented in the patient's medical record.
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nancy occurred, the drug could be discontinued, and it

would clear out of the body more quickly than fluoxetine
and its metabolite, norfluoxetine. Unfortunately, though,
little is published about the teratogenic effects of the
SSRis other than fluoxetine.
As a general rule, if a woman is being treated prior to
becoming pregnant or needs to begin treatment during
pregnancy, the lowest effective dose should be used for
the shortest possible period of time. Both parents must
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